COFCO Biotechnology Co (000930) Fair Value & Analysis
Basic Materials · CN · Market cap 9.1B CNY
Fair value as of: Jul 21, 2026
From 23 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from ¥2.15 to ¥1.10 (−48.8%) since Jun 25, 2026. Share price +7.3% over the past month.
A solid business, but screening 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.48). The favourable scenario is already priced in.
- The model range is unusually wide (¥0.5200 to ¥1.48). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range ¥4.25 – ¥11.00 · fair‑value band ¥0.5200 – ¥1.48 · the ¥4.71 price screens above the ¥1.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
COFCO Biotechnology Co (000930) currently trades at ¥4.71, while our model-based Fair Value estimate is ¥1.10, implying the stock looks roughly 76.7% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, COFCO Biotechnology Co generated revenue of 17.0B CNY at a net margin of -0.7%. Revenue declined 11.5% year over year. It earns a return on equity of -1.1%. Net debt stands at 2.4B CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥0.5200 (bear case) to ¥1.48 (bull case); at ¥4.71, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -77%, 000930 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models (¥8.27) versus Earnings-Based (¥0.1900). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
COFCO Biotechnology Co., Ltd., together with its subsidiaries, engages in the processing and production of biochemical products in China.
Full company description
COFCO Biotechnology Co., Ltd., together with its subsidiaries, engages in the processing and production of biochemical products in China. The company offers edible corn, special, waxy corn, and modified waxy corn starch; feed products, such as corn gluten meal, sprayed corn husk, corn germ meal, DDGS, fertilizer raw materials and glutamic acid residue; sweeteners comprising special syrup for frozen dough, compound fructose powder, maltodextrin, and fructose and glucose syrups; edible alcohol and fuel ethanol; and monosodium glutamate, anhydrous citric acid, potassium citrate, polylactic acid, phytosterols, and natural vitamin E. The company was formerly known as COFCO Biochemical (Anhui) Co., Ltd. and changed its name to COFCO Biotechnology Co., Ltd. in September 2019. The company was founded in 1998 and is based in Chaoyang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
COFCO Biotechnology Co reported revenue of ¥17.5B in FY2025 versus ¥23.6B in FY2021, a compound −7.1%/yr. Reported net income was ¥38.4M in FY2025, compounding −57.1%/yr from FY2021.
000930 screens 77% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 676 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare COFCO Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is COFCO Biotechnology Co (000930) overvalued or undervalued?
What is the fair value of 000930?
What is the quality score of 000930?
What is the revenue of COFCO Biotechnology Co (000930)?
What is the net profit margin of 000930?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track COFCO Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.